FIELD: medicine.
SUBSTANCE: group of inventions can be used for treating patients with non-radiation-axial spondylarthritis. That is ensured by administering an anti-IL-17 antibody such as secukinumab, or an antigen-binding fragment thereof. IL-17 antibody binds the epitope of IL-17 homodimer having two chains of mature IL-17 protein. Antibody to IL-17 or an antigen binding fragment has K D 100–200 pM and in vivo half-life of approximately 23–35 days. Also disclosed is a method of treating a patient having axial spondylarthritis.
EFFECT: group of inventions enables inhibiting the progression of structural injuries in the patients with non-radiographic axial spondylarthritis.
20 cl, 3 dwg, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF TREATING RHEUMATOID ARTHRITIS USING IL-17 ANTAGONISTS | 2011 |
|
RU2582937C2 |
| USE OF IL-17 ANTAGONISTS FOR INHIBITION OF STRUCTURAL DAMAGE PROGRESSION IN PATIENTS WITH PSORIATIC ARTHRITIS | 2015 |
|
RU2697383C2 |
| METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS | 2011 |
|
RU2591083C2 |
| METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS | 2011 |
|
RU2665954C1 |
| METHODS FOR PREVENTING OR TREATING ALLERGIES BY INTRODUCING AN IL-4R ANTAGONIST | 2017 |
|
RU2777328C2 |
| METHOD OF TREATING PSORIASIS (VERSIONS) | 2009 |
|
RU2497545C2 |
| SELECTIVE REDUCTION OF CYSTEINE RESIDUES IN ANTIBODIES AGAINST IL-17 | 2015 |
|
RU2719563C2 |
| SELECTIVE REDUCTION OF CYSTEINE RESIDUES IN ANTIBODIES AGAINST IL-17 | 2015 |
|
RU2765307C2 |
| METHODS OF TREATING PSORIASIS | 2008 |
|
RU2475265C2 |
| METHODS OF TREATING OR PREVENTING ASTHMA BY ADMINISTERING IL-4R ANTAGONIST | 2015 |
|
RU2713406C2 |
